Skip to main content
main-content

Heart failure

12-02-2021 | Dapagliflozin | News

Pooled analysis supports diabetes prevention effect of dapagliflozin

A pooled analysis of the DAPA-HF and DAPA-CKD trials suggests that taking the SGLT2 inhibitor dapagliflozin reduced the participants’ risk for developing type 2 diabetes by around a third.

11-19-2021 | Finerenone | News

Finerenone reduces HF risk in people with type 2 diabetes and CKD

Finerenone reduces the risk for new-onset heart failure, as well as hospitalization for heart failure (HHF) and death from HF, in people with type 2 diabetes and albuminuric chronic kidney disease, the latest analysis of FIGARO-DKD study data show.

11-01-2021 | Heart failure | News

Diabetic cardiomyopathy denotes high risk for progression to heart failure

The presence of cardiac abnormalities in people with diabetes forewarns of an increased risk for incident heart failure over the next few years, say researchers

10-28-2021 | Dapagliflozin | News

PRESERVED-HF: Dapagliflozin improves health status in people with HFpEF

Treatment with the SGLT2 inhibitor dapagliflozin improves symptoms and physical function in people with heart failure and preserved ejection fraction, suggest findings from the PRESERVED-HF trial.

10-07-2021 | SGLT2 inhibitors | News

Real-world data back SGLT2 inhibitor benefits even for people initially free of CVD

A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.

09-30-2021 | EASD 2021 | Conference coverage | News

AF, PAD, diabetes prevention data reported from DAPA-CKD

The latest DAPA-CKD data show the large absolute benefits of dapagliflozin treatment in people with peripheral artery disease or atrial fibrillation, and that the medication may reduce the risk for type 2 diabetes in people with initial prediabetes.

09-20-2021 | Heart failure | News

Gestational diabetes may flag early HF risk

The presence of gestational diabetes mellitus may identify women at an increased risk for experiencing hospitalization for heart failure within the next few years, research suggests.

08-29-2021 | ESC 2021 | Conference coverage | News

Empagliflozin has broad beneficial effect on HFpEF outcomes

Empagliflozin treatment produces significant reductions in the risk for a broad range of inpatient and outpatient heart failure outcomes in people with a preserved ejection fraction, shows further analysis of EMPEROR-Preserved.

Related topics

Superior

Related

Image Credits